 |
|
 |
- July 20, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"The Clinical Value of ApoB"Dr. Allan D. Sniderman (biography)
English - 2006-05-27 - 45 minutes
|
 | (57 slides) |
Summary :
"Lowering the level of atherogenic lipoproteins in plasma is unquestionably the single most important step that can be taken to reduce the complications of vascular disease," says Dr. Sniderman. How should this be done and does measurement of LDL-C provide an accurate picture of risk in all cases?
The apoB value represents the total number of circulating atherogenic lipoproteins, and is more useful for risk assessment when increased numbers of small-dense LDL (containing less cholesterol) are present. According to an expert panel report published this year by Barter and colleagues, evidence from fundamental, epidemiological and clinical trial studies show that apoB is "superior to any of the cholesterol indices to recognize those at increased risk of vascular disease and to judge the adequacy of lipid-lowering therapy." (1). "The number of atherogenic particles on therapy is the determinant of the residual risk due to lipoproteins," says Dr. Sniderman.
Dr. Sniderman further discusses the value of apoB compared to non-HDL-C and triglycerides, and shows new data from the CARDS study indicating the on-treatment apoB as a more accurate predictor of outcome than LDL-C for the primary endpoint and coronary artery disease in type 2 diabetic patients.
Copyright © 2006 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Limitations of LDL-C for risk assessment
- The value of apoB vs LDL-C for estimating cardiovascular risk and guiding therapy
- New data from CARDS: On-treatment apoB as a predictor of outcome in type 2 diabetic patients
- Approach to lowering apoB
Bibliographic references :
Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Jungner I, Krauss RM, Kwiterovich P, Marcovina S, Packard CJ, Pearson TA, Reddy KS, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KM. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006 Mar;259(3):247-58.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
